

L-Fucose from Vitamin C with Only Acetonide Protection

Zilei Liu,^{†,‡} Akihito Yoshihara,[§] Mark R. Wormald,[‡] Sarah F. Jenkinson,[†] Vicky Gibson,^{||} Ken Izumori,^{*,§} and George W. J. Fleet^{*,†}

[†]Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford, OX1 3TA, U.K.


[‡]Oxford Glycobiology Institute, University of Oxford, Oxford, OX1 3QU, U.K.

[§]Rare Sugar Research Center, Kagawa University, 2393 Ikenobe, Mikicho, Kita-gun, Kagawa 761-0795, Japan

^{||}Carbosynth Limited, 8, Old Station Business Park, Compton, Berkshire, RG20 6NE, U.K.

Supporting Information

ABSTRACT: Addition of human milk oligosaccharides (HMO) to baby foods may protect infants from disease. As many simple HMOs are fucosylated this is likely to increase the demand for L-fucose as a synthetic building block. Any chemical synthesis must be cheap to compete with a biotechnological process. Acetonide is the only protecting group we have used in this new synthesis of L-fucose from vitamin C in 27% overall yield (purification by recrystallization; no chromatography required in the entire sequence).



L-Fucose **1** is a monosaccharide that is a common component of many glycolipids, and *N*- and *O*-linked glycans in mammalian cells; fucosylated glycans have many functions and are often regulated during ontogeny and cellular differentiation.¹ Alterations in the expression of fucosylated oligosaccharides are found in several pathological processes, including cancer and atherosclerosis.² Fucosylated human milk oligosaccharides (HMO) protect infants from disease³ and are important in the development and protection of newborn infants.⁴ Addition of HMOs as a baby food supplement would sharply increase the demand for fucose. There is thus considerable interest in the biotechnological⁵ and chemical⁶ synthesis of HMOs; all such syntheses involve the use of fucose as a starting material. At present, almost all fucose is produced by acid hydrolysis or microbial fermentation of sulfated polysaccharides such as fucoidans.⁷ For a chemical synthesis to compete, it is necessary that the starting material and reagents are cheap and the process involves minimum purification. This paper describes the synthesis of fucose from vitamin C **2**, a bulk chemical which costs \$3–\$4 per kg [for 1000 kg].⁸

Palladium-catalyzed hydrogenation of vitamin C **2** formed L-gulonolactone **3**⁹ (99%) which on treatment with acetone and *p*-toluenesulfonic acid (*p*TSA) gave the diacetonide **4** in 93% yield¹⁰ [Scheme 1]. The diacetonide **4** and its enantiomer¹¹ have been used in several scalable syntheses.¹²

Addition of methyl lithium to lactone **4** afforded the lactols **5** in 96% yield; although **5** can be easily crystallized as the α -anomer,¹³ the crude residue was used in the next step. Reduction of **5** by sodium borohydride in methanol afforded a mixture of the two 1-deoxyheptitols **6** and **7** in a ratio of 93:7

(95% yield); diastereoselectivity in similar systems has been rationalized by a Felkin–Ahn controlled addition of hydride.¹⁴ The methyl signals in **6** and **7** allow accurate measurements of the ratio by ¹H NMR. Hydrolysis of the mixture of **6** and **7** by Dowex (50W X8, H⁺) in methanol/water gave the 1-deoxyheptitols **8** and **9** in a ratio of 93:7 as shown by both NMR and HPLC.


Crystallization of the mixture from water/methanol/acetonitrile gave the deoxyheptitols **8** and **9** in a ratio of 98:2 (81% yield; 74% from the diacetonide **4**). The mother liquor from the crystallization contained **8** and **9** in a ratio of ~4:3 and allowed pure samples of the two heptitols to be isolated by HPLC. The deoxyheptitol **8** was easily crystallized,¹⁵ whereas **9** was an oil.¹⁶ Cleavage of the terminal diol in **8** by periodate would give fucose **1**; cleavage of terminal diols is usually more rapid than other diol oxidations.¹⁷ Similar oxidation of **9** would give the C5 epimer of fucose, 6-deoxy-D-altrose.¹⁸ However, ¹H NMR studies of the direct oxidation of **8** by aqueous periodate did not indicate formation of any fucose, so protection of the heptitol **8** was necessary.

Treatment of **8** with acetone in the presence of *p*-toluenesulfonic acid gave the kinetic triacetonide **10** (83%). Although **10** is also the most stable triacetonide derived from **8**, longer reaction times and alternative reaction conditions gave small amounts of other acetonides. Accordingly, the reaction was stopped when other products began to appear; pure

Received: September 16, 2014

Published: October 13, 2014

Scheme 1. Synthesis of L-Fucose 1



crystalline **10** was isolated by extraction of the crude residue with cyclohexane. The residue was subjected to the same reaction conditions to give **10** in 83% yield. Kinetic hydrolysis of the terminal acetonide in **10** by acetic acid in aqueous methanol gave the diol **11** in 81% yield. The most efficient procedure involved following the reaction by TLC; initially only **11** was formed. When other products began to appear, the reaction was quenched with NaHCO_3 (aq, sat). Unreacted triacetone **10** and the diacetone **11** were efficiently recovered by sequential extraction with cyclohexane and ethyl acetate. Both the triacetone **10** and the diacetone **11** are crystalline materials; no chromatography is necessary at any stage during the synthesis. Treatment of the diol **11** with sodium periodate adsorbed on silica gel¹⁹ afforded the aldehyde **12** (80%) from which the acetonides were removed by Dowex (50W X8, H^+) in water to give a 100% yield of fucose **1** with a purity, as established by HPLC, of 95.9%. A single crystallization of fucose from ethanol increased the purity to 99.3% in a yield of 74% [see Supporting Information]. The overall yield of crystalline fucose **1** from the diacetone **4** is 30% (27% from vitamin C **2**). No chromatography was involved in the entire sequence; crystallizations of both the heptitol **8** and fucose **1** were efficient. The residue from the mother liquor of crystallization of fucose contained ~50% fucose; on an industrial scale, there are well-established chromatographic procedures²⁰ for the purification of fucose so that the overall yield would be higher.

The preparation of fucose by periodate cleavage of a deoxyheptitol, derived from addition of methyl lithium to diacetone mannose, was previously described; a different protecting group strategy was employed.¹⁷ Fucose has been prepared from other monosaccharides,¹ most commonly by

adjusting the oxidation levels at C1 and C6 of derivatives of D-galactose, L-galactose, and D-galacturonic acid.²¹ Acetonides have been recognized as the optimum protecting group since the dawn of monosaccharide chemistry.²² As in an approach to L-glucose,²³ the solubility of the seven carbon sugar triacetone **11** in cyclohexane is crucial for the success of this multi gram synthesis of fucose. The biotechnology of Izumoring²⁴ allows the conversion of L-rhamnose, the only cheap deoxyhexose, into many other 6- and 1-deoxyhexoses;²⁵ however, the isomerization of rhamnose to fucose is not efficient.

Although fucose is the 6-deoxyhexose with a well-established demand, there is considerable interest in the synthesis of other deoxyhexoses, particularly as building blocks for their incorporation into oligosaccharides.²⁶ The strategy of addition of methyl lithium to sugar lactones gives a 1-deoxy-ketose which may be stereoselectively reduced to 1,2-*syn* diols (as in this paper) or under chelation controlled conditions²⁷ to 1,2-*anti*-diols. Elaboration of each epimeric 1-deoxyheptitol through the triacetones will generate two 6-deoxyhexoses. Since some six hexonolactones [the enantiomers of *gluco-*, *gulono-*, and *galactono-* lactones] are easily available, some 12 of the 16 6-deoxyhexoses may be accessed by this strategy.

Almost all sugars that are available on industrial scale are made by biotechnology;²⁸ even the Reichstein process involving chemistry for 80 years²⁹ for the synthesis of vitamin C **2** has been mostly superseded by a fermentation process developed in China.³⁰ However, this scalable synthesis of fucose from vitamin C may be competitive with the present biotechnological procedures.

■ ASSOCIATED CONTENT

Supporting Information

Experimental procedures and full spectroscopic data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: george.fleet@chem.ox.ac.uk

*E-mail: izumori@ag.kagawa-u.ac.jp

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the Leverhulme Trust (G.W.J.F.).

■ REFERENCES

- (1) (a) Becker, D. J.; Lowe, J. B. *Glycobiology* **2003**, *13*, 41R–47R. (b) Vanhooren, P. T.; Vandamme, E. J. *J. Chem. Technol. Biotechnol.* **1999**, *74*, 479–497.
- (2) (a) Kwak, J. Y. *Marine Drugs* **2014**, *12*, 851–870. (b) Merino, P.; Tejero, T.; Delso, I.; Hurtado-Guerrero, R.; Gomez-SanJuan, A.; Sadaba, D. *Mini-Rev. Med. Chem.* **2012**, *12*, 1455–1464.
- (3) (a) Bode, L. *Glycobiology* **2012**, *22*, 1147–1162. (b) Peterson, R.; Cheah, W. Y.; Grinyer, J.; Packer, N. *Glycobiology* **2013**, *23*, 1425–1438.
- (4) Ballard, O.; Morrow, A. L. *Pediatr. Clin. North Am.* **2013**, *60*, 49–74.
- (5) Han, N. S.; Kim, T. J.; Park, Y. C.; Kim, J.; Seo, J. H. *Biotechnol. Adv.* **2012**, *30*, 1268–1278.
- (6) Jennum, C. A.; Fenger, T. H.; Bruun, L. M.; Madsen, R. *Eur. J. Org. Chem.* **2014**, 3232–3241.

- (7) (a) Hefferon, K. L. *Recent Patents on Biotechnology* **2012**, *6*, 97–105. (b) Vanhooren, P. T.; Vandamme, E. J. *Prog. Biotechnol.* **2000**, *17*, 109–114. (c) Vanhooren, P. T.; De Baets, S.; Bruggeman, G.; Vandamme, E. J. In *Encyclopedia of Food Microbiology*, Vol. 2; Robinson, R., Batt, C., Patel, P., Eds.; Academic Press Ltd.: UK, 2000; pp 1107–1115.
- (8) Quotes from reputable companies via alibaba.com on 08/22/14.
- (9) (a) Andrews, G. C.; Crawford, T. C.; Bacon, B. E. *J. Org. Chem.* **1981**, *46*, 2976–2977. (b) Vekemans, J. A. J. M.; Boerekamp, J.; Godefroi, E. F.; Chittenden, G. J. F. *Recueil Trav. Chim. Pays-Bas* **1985**, *104*, 266–272.
- (10) Sano, H.; Sugai, S. *Tetrahedron: Asymmetry* **1995**, *6*, 1143–1150.
- (11) (a) Crawford, T. C. *Adv. Carbohydr. Chem. Biochem.* **1981**, *38*, 287–321. (b) Ogura, H.; Takahashi, H.; Itoh, T. *J. Org. Chem.* **1972**, *37*, 72–75.
- (12) (a) Hering, K. W.; Karaveg, K.; Moremen, K. W.; Pearson, W. H. *J. Org. Chem.* **2005**, *70*, 9892–9904. (b) Fleet, G. W. J.; Ramsden, N. G.; Witty, D. R. *Tetrahedron* **1989**, *45*, 319–326. (c) Fleet, G. W. J.; Ramsden, N. G.; Nash, R. J.; Fellows, L. E.; Jacob, G. S.; di Bello, I. C.; Winchester, B. *Carbohydr. Res.* **1990**, *205*, 269–282. (d) Fleet, G. W. J.; Son, J. C. *Tetrahedron* **1988**, *44*, 2637–2647. (e) Clinch, K.; Evans, G. B.; Fleet, G. W. J.; Furneaux, R. H.; Johnson, S. W.; Lenz, D.; Mee, S.; Rands, P. R.; Schramm, V. L.; Ringia, E. A. T.; Tyler, P. C. *Org. Biomol. Chem.* **2006**, *4*, 1131–1139.
- (13) Beacham, A. R.; Biggadike, K.; Taylor, H. E.; Hackett, L.; Winchester, B. G.; Watkin, D. J.; Fleet, G. W. J. *J. Chem. Soc., Chem. Commun.* **1994**, 2001–2002.
- (14) (a) Masaguer, C. F.; Bleriot, Y.; Charlwood, J.; Winchester, B. G.; Fleet, G. W. J. *Tetrahedron* **1997**, *53*, 15147–15156. (b) Bleriot, Y.; Masaguer, C. F.; Charlwood, J.; Winchester, B. G.; Lane, A. L.; Crook, S.; Watkin, D. J.; Fleet, G. W. J. *Tetrahedron* **1997**, *53*, 15135–15146.
- (15) (a) Votocek, E. *Collect. Czech. Chem. Commun.* **1938**, *10*, 273–277. (b) Lewis, D. J. *Chem. Soc., Perkin Trans. 2* **1991**, 197–200.
- (16) 1-Deoxy-L-glycero-D-talo-heptitol [7-deoxy-D-glycero-D-gluco-heptitol] **7** has not been previously reported.
- (17) Gesson, J.-P.; Jacquesy, J.-C.; Mondon, M.; Petit, P. *Tetrahedron Lett.* **1992**, *33*, 3637–3640.
- (18) (a) Tako, M.; Dobashi, Y.; Shimabukuro, J.; Yogi, T.; Uechi, K.; Tamaki, Y.; Konishi, T. *Carbohydr. Polym.* **2013**, *92*, 2135–2140. (b) Tako, M.; Dobashi, Y.; Tamaki, Y.; Konishi, T.; Yamada, M.; Ishida, H.; Kiso, M. *Carbohydr. Res.* **2012**, *350*, 25–30. (c) Yamada, M.; Yoshida, F.; Ando, H.; Ishida, H.; Kiso, M.; Tako, M. *Heterocycles* **2011**, *82*, 1699–1704.
- (19) Zhong, Y.-L.; Shing, T. K. M. *J. Org. Chem.* **1997**, *62*, 2622–2624.
- (20) (a) Saari, P.; Hurme, M. *Chem. Eng. Technol.* **2011**, *34*, 282–288. (b) Saari, P.; Hakka, K.; Heikkilä, H.; Jumppanen, J.; Hurme, M. *J. Liquid Chromatog. Related Technol.* **2009**, *32*, 2050–2064.
- (21) Schroven, A.; Dekany, G.; Róhrig, C.; Vrasidas, I.; Pérez, I. F.; Hederos, M.; Boutet, J.; Kröger, L.; Kovács-Pénzes, P.; Horváth, F.; Risinger, C.; Pipa, G. WO20130245250, 2013.
- (22) Hough, L.; Richardson, A. C. In *Rodd's Chemistry of Carbon Compounds*, Vol. 1F; Elsevier: Amsterdam, 1967; pp 167–595.
- (23) Martínez, R. F.; Liu, Z.; Glawar, A. F. G.; Yoshihara, A.; Izumori, K.; Fleet, G. W. J.; Jenkinson, S. F. *Angew. Chem., Int. Ed.* **2014**, *53*, 1160–1162.
- (24) (a) Izumori, K. *Naturwissenschaften* **2002**, *89*, 120–124. (b) Izumori, K. *J. Biotechnol.* **2006**, *124*, 717–722.
- (25) (a) Gullapalli, P.; Yoshihara, A.; Morimoto, K.; Rao, D.; Jenkinson, S. F.; Wormald, M. R.; Fleet, G. W. J.; Izumori, K. *Tetrahedron Lett.* **2010**, *51*, 895–898. (b) Yoshihara, A.; Haraguchi, S.; Gullapalli, P.; Rao, D.; Morimoto, K.; Takata, G.; Jones, N. A.; Jenkinson, S. F.; Wormald, M. R.; Dwek, R. A.; Fleet, G. W. J.; Izumori, K. *Tetrahedron: Asymmetry* **2008**, *19*, 739–745. (c) Gullapalli, P.; Shiji, T.; Rao, D.; Yoshihara, A.; Morimoto, K.; Takata, G.; Fleet, G. W. J.; Izumori, K. *Tetrahedron: Asymmetry* **2007**, *18*, 1995–2000. (d) Jones, N. A.; Jenkinson, S. F.; Soengas, R.; Fanefjord, M.; Wormald, M. R.; Dwek, R. A.; Kiran, G. P.; Devendar, R.; Takata, G.;